#Israel #Herzliya #Corundum Neuroscience #NextSense #Smartbuds

Corundum Neuroscience's Investment in NextSense

Corundum Neuroscience (CNS), a notable player in the neuroscience venture space, has announced its recent participation in a Series A funding round for the innovative company NextSense, which specializes in wearable EEG technology. This strategic investment marks an important milestone in CNS's ongoing mission to commercialize cutting-edge neuroscience solutions aimed at improving brain health.

NextSense is renowned for developing Smartbuds, a state-of-the-art product designed to help users enhance their sleep quality and overall brain function through scientifically validated audio stimulation. As part of their commitment to pushing the boundaries of neuroscience, Corundum Neuroscience has invested in NextSense to accelerate its growth and help bring these groundbreaking in-ear EEG earbuds to market by the fourth quarter of 2025.

PhD Itsik Francis, the Managing Partner for Business Development at Corundum Neuroscience, expressed enthusiasm about the investment, stating, "We are always looking for cutting-edge neuroscience solutions that improve brain health, making NextSense a perfect addition to our portfolio. We are excited to support the NextSense team to bring clinical-grade EEG monitoring to consumers, enabling them to better understand and improve their sleep."

The Smartbuds utilize clinical-grade EEG technology, allowing users to accurately track sleep stages and improve sleep depth. Reports indicate that preliminary users have experienced slow-wave sleep improvements of up to 50%, thanks to auditory stimulation provided through the earbuds. This innovative approach empowers users with practical insights into their sleep patterns, thus promoting cleaner paths to enhanced health and well-being.

Jonathan Berent, the Founder and CEO of NextSense, shared his excitement about this partnership: "We're excited to partner with Corundum Neuroscience. Their extensive experience with innovative neuroscience companies makes them an invaluable ally in our quest to launch Smartbuds everywhere. By democratizing brain health, we aim to provide accessible solutions that genuinely improve people's lives."

Corundum Neuroscience operates as a venture builder and fund dedicated to transforming laboratory findings into practical solutions for real-world health challenges. With a unique blend of domain expertise and a track record of success in venture building, the organization focuses on long-term investments that contribute to enhancing health, longevity, and quality of life.

Founded in September 2023 by former executives from Joy Ventures, Corundum Neuroscience is headquartered in Herzliya, Israel. Its mission emphasizes the importance of supporting researchers, entrepreneurs, and startups as they navigate the complex journey from concept to market.

Meanwhile, NextSense's headquarters are located in Mountain View, California, positioning them at the heart of the tech and wellness revolution. After investing years in research and clinical trials, NextSense has achieved significant breakthroughs, ultimately leading to the development of Smartbuds—an everyday wearable that blends neuroscience with impeccable design for better brain health outcomes.

As the industry gears up for the product launch in late 2025, both Corundum Neuroscience and NextSense are poised to make a lasting impact on the consumer wellness market, signifying a new era in personal brain health management. Stay tuned for further updates on the rollout of Smartbuds and other exciting developments in the neuroscience arena.

For more information, readers can follow Corundum Neuroscience on LinkedIn or visit their website at cnsfund.com.